Kissei Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company that specializes in the research, development and manufacture of prescription drugs across a range of therapeutic areas. Founded in 1946 and incorporated in 1950, Kissei has built a reputation for its work in urology, nephrology, endocrinology, respiratory medicine and oncology. Through its dedicated in-house research centers, the company advances novel small molecules and biologic candidates from early discovery through clinical development.
The company’s product portfolio includes treatments for benign prostatic hyperplasia, chronic kidney disease, type 2 diabetes and various forms of cancer. Kissei also engages in the production of immunomodulatory and anti‐inflammatory agents. Its manufacturing facilities adhere to stringent quality standards, supplying both domestic and international markets. In recent years, the company has pursued strategic partnerships and licensing agreements to expand its late-stage pipeline and bring new therapies to patients worldwide.
Headquartered in Matsumoto, Nagano Prefecture, Kissei serves a global patient base through its subsidiaries and distribution channels in Asia, Europe and North America. The company maintains collaborative relationships with academic institutions, contract research organizations and other pharmaceutical firms to bolster its R&D capabilities. This network supports Kissei’s efforts to identify unmet medical needs and accelerate the clinical translation of promising drug candidates.
Kissei’s governance is led by a board of directors and senior management team with deep expertise in drug discovery, regulatory affairs and commercial strategy. Through a combination of organic growth and targeted alliances, the company seeks to strengthen its market position and deliver sustainable value for patients, healthcare providers and shareholders alike.
AI Generated. May Contain Errors.
Free KSPHF Stock Alerts